0.793
price down icon0.28%   -0.0022
pre-market  Pre-market:  .82   0.027   +3.40%
loading
Inflarx N V stock is traded at $0.793, with a volume of 228.13K. It is down -0.28% in the last 24 hours and down -57.14% over the past month. InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$0.7952
Open:
$0.78
24h Volume:
228.13K
Relative Volume:
0.49
Market Cap:
$56.79M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-0.9176
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
+1.67%
1M Performance:
-57.14%
6M Performance:
-68.28%
1Y Performance:
-48.51%
1-Day Range:
Value
$0.77
$0.8179
1-Week Range:
Value
$0.75
$0.8318
52-Week Range:
Value
$0.7113
$2.815

Inflarx N V Stock (IFRX) Company Profile

Name
Name
Inflarx N V
Name
Phone
-
Name
Address
-
Name
Employee
74
Name
Twitter
Name
Next Earnings Date
2025-03-21
Name
Latest SEC Filings
Name
IFRX's Discussions on Twitter

Compare IFRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IFRX
Inflarx N V
0.793 56.79M 0 -46.12M -41.02M -0.8642
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.54 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
511.92 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
313.13 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
540.76 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.51 28.51B 3.81B -644.79M -669.77M -6.24

Inflarx N V Stock (IFRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-29-25 Downgrade Raymond James Strong Buy → Outperform
Apr-29-25 Initiated Cantor Fitzgerald Overweight
Apr-05-23 Upgrade Guggenheim Neutral → Buy
Feb-28-22 Downgrade Guggenheim Buy → Neutral
Oct-28-21 Upgrade Raymond James Outperform → Strong Buy
Mar-11-21 Upgrade Guggenheim Neutral → Buy
Nov-06-20 Upgrade SVB Leerink Mkt Perform → Outperform
Oct-08-20 Initiated H.C. Wainwright Buy
Jun-17-20 Initiated BTIG Research Buy
Apr-30-20 Upgrade Raymond James Mkt Perform → Outperform
Jun-05-19 Downgrade BMO Capital Markets Outperform → Market Perform
Jun-05-19 Downgrade Guggenheim Buy → Neutral
Jun-05-19 Downgrade JP Morgan Overweight → Underweight
Jun-05-19 Downgrade Robert W. Baird Outperform → Neutral
Jun-05-19 Downgrade SunTrust Buy → Hold
Jan-29-19 Initiated Robert W. Baird Outperform
Dec-10-18 Initiated Credit Suisse Outperform
Jul-13-18 Initiated BMO Capital Markets Outperform
Jun-28-18 Initiated Raymond James Outperform
Jun-28-18 Initiated SunTrust Buy
Feb-08-18 Initiated B. Riley FBR, Inc. Buy
View All

Inflarx N V Stock (IFRX) Latest News

pulisher
Jun 13, 2025

Analyzing InflaRx (NASDAQ:IFRX) and Inhibitor Therapeutics (OTCMKTS:INTI) - Defense World

Jun 13, 2025
pulisher
Jun 11, 2025

Brokers Offer Predictions for InflaRx FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 07, 2025

InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events - The Globe and Mail

Jun 07, 2025
pulisher
Jun 05, 2025

InflaRx (NASDAQ:IFRX) Short Interest Update - Defense World

Jun 05, 2025
pulisher
May 30, 2025

InflaRx (NASDAQ:IFRX) Price Target Cut to $3.00 by Analysts at Oppenheimer - Defense World

May 30, 2025
pulisher
May 30, 2025

InflaRx stock rating cut, price target slashed to $2 by Raymond James - Investing.com Nigeria

May 30, 2025
pulisher
May 29, 2025

InflaRx (IFRX) Maintains Outperform Rating, Price Target Adjusted | IFRX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

IFRX Price Target Cut as Phase 3 Trial Halts | IFRX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Guggenheim maintains $10 target on Inflarx despite study halt - Investing.com Australia

May 29, 2025
pulisher
May 29, 2025

InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Sto - GuruFocus

May 29, 2025
pulisher
May 29, 2025

InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

InflaRx downgraded to Outperform from Strong Buy at Raymond James - TipRanks

May 29, 2025
pulisher
May 28, 2025

Top Midday Decliners - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Crude Oil Gains 2%; Macy's Lowers Earnings Forecast - Benzinga

May 28, 2025
pulisher
May 28, 2025

Guggenheim maintains $10 target on Inflarx despite study halt By Investing.com - Investing.com Nigeria

May 28, 2025
pulisher
May 28, 2025

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga

May 28, 2025
pulisher
May 28, 2025

PG rating: Inflarx review declares phase III bomb - BioWorld MedTech

May 28, 2025
pulisher
May 28, 2025

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial - insights.citeline.com

May 28, 2025
pulisher
May 28, 2025

Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews

May 28, 2025
pulisher
May 28, 2025

InflaRx (IFRX) Halts Key Drug Trials, Refocuses Strategy - GuruFocus

May 28, 2025
pulisher
May 28, 2025

InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum - TipRanks

May 28, 2025
pulisher
May 28, 2025

InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

InflaRx stock plunges on plans to drop lead asset (IFRX:NASDAQ) - Seeking Alpha

May 28, 2025
pulisher
May 28, 2025

InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus - GuruFocus

May 28, 2025
pulisher
May 28, 2025

InflaRx to discontinue vilobelimab indication following IDMC recommendation - TipRanks

May 28, 2025
pulisher
May 28, 2025

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire

May 28, 2025
pulisher
May 28, 2025

Clinical Trial Setback: InflaRx Discontinues Key Drug Program After Phase 3 Futility Results - Stock Titan

May 28, 2025
pulisher
May 27, 2025

InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp - Defense World

May 27, 2025
pulisher
May 22, 2025

InflaRx to Participate in Upcoming Investor Conferences - The Manila Times

May 22, 2025
pulisher
May 22, 2025

InflaRx Sets Ambitious Investor Conference Tour: Jefferies, Oppenheimer, and Leerink Partners Ahead - Stock Titan

May 22, 2025
pulisher
May 20, 2025

Cubist Systematic Strategies LLC Makes New Investment in InflaRx (NASDAQ:IFRX) - Defense World

May 20, 2025
pulisher
May 16, 2025

Schonfeld Strategic Advisors LLC Sells 7,756 Shares of InflaRx (NASDAQ:IFRX) - Defense World

May 16, 2025
pulisher
May 14, 2025

Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Certain Options of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com

May 14, 2025
pulisher
May 13, 2025

Raymond James maintains Strong Buy on Inflarx stock, $13 target By Investing.com - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Raymond James maintains Strong Buy on Inflarx stock, $13 target - Investing.com

May 13, 2025
pulisher
May 12, 2025

FY2025 EPS Estimates for InflaRx Raised by Cantor Fitzgerald - Defense World

May 12, 2025
pulisher
May 12, 2025

Q2 Earnings Forecast for InflaRx Issued By Leerink Partnrs - Defense World

May 12, 2025
pulisher
May 11, 2025

InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024) - Yahoo Finance

May 11, 2025
pulisher
May 08, 2025

Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform Recommendation - Nasdaq

May 08, 2025
pulisher
May 08, 2025

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga

May 08, 2025
pulisher
May 08, 2025

InflaRx N.V. Reports Q1 2025 Financial Results - TipRanks

May 08, 2025
pulisher
May 07, 2025

InflaRx reports Q1 EPS (EUR 0.13) vs (EUR 0.17) last year - TipRanks

May 07, 2025
pulisher
May 07, 2025

InflaRx Reports Q1 2025 Financial Results with Reduced Losses - TipRanks

May 07, 2025
pulisher
May 07, 2025

InflaRx (IFRX) Awaits Key Milestones in Drug Development | IFRX Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

InflaRx N.V. Announces Progress in Toxicology Studies for INF904 and Upcoming Phase 3 Interim Analysis of Vilobelimab - Nasdaq

May 07, 2025
pulisher
May 07, 2025

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 07, 2025
pulisher
May 05, 2025

InflaRx NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView

May 05, 2025

Inflarx N V Stock (IFRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.68
price down icon 2.27%
$35.40
price up icon 1.55%
$20.39
price down icon 0.83%
$105.42
price up icon 2.67%
$103.01
price down icon 3.30%
biotechnology ONC
$257.51
price up icon 4.22%
Cap:     |  Volume (24h):